
- BioPharm International, June 2022 Issue
- Volume 35
- Issue 6
- Pages: 48
Next-Generation Cas9 Proteins
Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.
Thermo Fisher Scientific’s Invitrogen TrueCut Hifi Cas9 Protein is designed for research applications that require highly precise genome editing, such as the engineering of chimeric antigen receptor (CAR)-T cells and the creation of cellular models for disease discovery.
The Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency. It does this by minimizing edits in unintended locations, which are disruptive in translational research, drug screening, and drug modeling. It has demonstrated near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), as well as shown improved off-target profiles relative to similar proteins.
Articles in this issue
over 3 years ago
Early Strategizing Tightens Development Timelinesover 3 years ago
Employing Genomics Tools to Accelerate Drug Developmentover 3 years ago
Considerations for US Fetal Bovine Serum Sourcingover 3 years ago
Advancing Process Chromatography in DSPover 3 years ago
Pre-filled Syringes Show Strong Growthover 3 years ago
GMPs for Sterile Manufacturing of Biologicsover 3 years ago
Method Development for Biosimilar Analysisover 3 years ago
When Is It Appropriate to Outsource Bioanalysis Work to a CRO?over 3 years ago
FDA to Continue Inspection Efficiencies After PandemicNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.